United States was the largest of Teva Pharmaceutical Industries Ltd’s 2 reported lines in fiscal 2025, at $7.08B — 58% of $12.12B.
| Geography | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | — | — | — | |||||||||||||
| United States | $5.55B | $6.33B | $7.08B | |||||||||||||
| Salesrevenuenet | — | — | — | |||||||||||||
| Europe | $4.84B | $5.10B | $5.04B | |||||||||||||
| Total | $10.39B | $11.43B | $12.12B |
In fiscal 2025, which ended December 31, 2025, the 2 regions Teva Pharmaceutical Industries Ltd reported in this breakdown added up to $12.12B. That was up 6.0% from $11.43B in fiscal 2024. United States was the largest region, at $7.08B or 58.4% of the total, followed by Europe ($5.04B, 41.6%).
Compared with fiscal 2024, United States grew the fastest, rising 11.9% to $7.08B. Europe fell the most, down 1.2% to $5.04B. Over fiscal 2023 to 2025, revenue across these regions went from $10.39B to $12.12B, a compound annual growth rate of 8.0%. United States' share of the total rose from 53.5% to 58.4% over the same years.
The table also keeps 2 regions that Teva Pharmaceutical Industries Ltd no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers 16 fiscal years between 2008 and 2025, as reported in Teva Pharmaceutical Industries Ltd's annual filings.
Teva Pharmaceutical Industries Ltd (TEVA) breaks its revenue down by region. In fiscal 2025, its largest region was United States, with $7.08B or 58.4% of the total, followed by Europe at $5.04B (41.6%).
United States was Teva Pharmaceutical Industries Ltd's largest region in fiscal 2025, with $7.08B in revenue, 58.4% of the $12.12B reported across its 2 regions.
Of the Teva Pharmaceutical Industries Ltd regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, United States grew the fastest, rising 11.9% from $6.33B to $7.08B.
Every figure is taken from Teva Pharmaceutical Industries Ltd's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2008 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.